MSS/ MMRp

我们是谁

  • 4 月 5, 2022
    难治性转移性结直肠癌患者的 NKG2D CAR-NK 细胞疗法
  • 4 月 5, 2022
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
  • 4 月 5, 2022
    Trial Of Pembrolizumab And Nintedanib
  • 4 月 5, 2022
    Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
  • 4 月 5, 2022
    COLLISION 试验 - 结直肠肝转移：手术与热消融
  • 4 月 5, 2022
    转移性结直肠癌中的福格替尼、替利珠单抗和立体定向消融放疗联合疗法（RIFLE）
  • 4 月 5, 2022
    结直肠癌患者肝移植与化疗的比较
  • 4 月 5, 2022
    Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
  • 4 月 5, 2022
    HLX208（BRAF V600E 抑制剂）联合西妥昔单抗治疗一线治疗后出现 BRAF V600E 突变的转移性结直肠癌 (mCRC) 的疗效观察
  • 4 月 5, 2022
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)